Evidence Gaps in the Identification and Treatment of Hypertension in Children

A Multivariate prediction model for amlodipine therapeutic efficacy in pediatric primary hypertension

Background

There are currently no biomarker-based prediction models for amlodipine therapeutic efficacy in pediatric hypertension. This study aimed to identify potential biomarkers and establish a biomarker-based model for predicting amlodipine therapeutic efficacy in pediatric primary hypertension (PH).

Methods

From January 2022 to December 2023, 165 children and adolescents with PH prescribed amlodipine were recruited at our department for a prospective observational study. Patients were grouped into Responders and Non-responders after one month treatment. The baseline data in the two groups were analyzed to identify variables associated with amlodipine treatment responsiveness; furthermore, a nomogram prediction model was established based on those potential predictors derived from multivariate regression analysis. This model's discrimination and calibration were evaluated by a series of statistical methods and internal validation was done using the bootstrap sampling method (1000 resamples).

Results

Eighty-nine patients responded to amlodipine while 76 did not. After statistical adjustment, 4 variables were found to be independently associated with therapeutic efficacy, including hyperinsulinemia (OR = 3.000, 95% CI: 1.409-6.386, p  = 0.004), insulin resistance (OR = 2.354, 95% CI: 1.032-5.370, p = 0.042), the baseline plasma Endothelin-1 level (OR = 0.627, 95% CI: 0.532-0.740, p < 0.001) and amlodipine dosages (OR = 1.743, 95% CI: 1.400-2.169, p <0.001). Compared to the baseline model, the full model with the four variables had a good calibration with an area under the curve (AUC) of 0.967 (95% CI: 0.945-0.990), yielding a sensitivity and a specificity of 91.0% and 92.1%, respectively; the clinical decision curve showed a positive net benefit. Additionally, a nomogram model was established based on the four variables and evaluated by bootstrap internal validation with the c-statistic of 0.865 and the calibration curve being close to the ideal line (p > 0.05).

Conclusion

A nomogram model with high predictive value for amlodipine therapeutic efficacy in pediatric PH was established. This model may be potentially applied to guide the selection of amlodipine for the treatment of pediatric PH.

Predicting Childhood and Adolescence Hypertension: Analysis of Predictors Using Machine Learning

BACKGROUND

There has been a substantial burden of hypertension in children and adolescents. Given the availability of primary prevention strategies, it is important to determine predictors for early identification of children and adolescents at risk of hypertension. This study aims to attempt and validate machine learning (ML) algorithms for accurately predicting blood pressure (BP) status (normal, prehypertension, and hypertension) over 1- and 3-year periods, identifying key predictors without compromising model performance.

METHODS

We included a population-based cohort of primary 1 to secondary 6 students (typically aged 6 to 18 years) during the academic years of 1995 to 1996 and 2019 to 2020 in Hong Kong. Thirty-six easy-assessed predictors were initially model childhood BP status. Multiple ML algorithms, decision tree, random forest, k-nearest neighbor, eXtreme Gradient Boosting (XGBoost), and multinomial logistic regression (MLR), were used. Model evaluation was performed by various accuracy metrics. The Shapley Additive Explanations (SHAP) was used to identify key features for both predictions.

RESULTS

A total of 923 301 and 602 179 visit pairs were used for the 1- and 3-year predictions, respectively. XGBoost demonstrated the highest prediction accuracies for 1-year (macro-area under the receiver operating characteristic curve [AUROC] = 0.92, micro-AUROC = 0.91) and 3-year (macro-AUROC = 0.91, micro-AUROC = 0.90) periods. The traditional MLR approach had the lowest accuracies for 1- (macro-AUROC = 0.70, micro-AUROC = 0.68) and 3-year (macro-AUROC = 0.70, micro-AUROC = 0.68) predictions. The SHAP values identified 17 key predictors without the need for direct BP measurements or laboratory tests.

CONCLUSION

ML prediction models can accurately predict childhood prehypertension and hypertension at 1 and 3 years, independent of BP and laboratory measurements. The identified key predictors may inform areas for personalized prevention in hypertension.

Hypertension in Children and Young Adults

Primary hypertension (PH) is most common during adolescence with increasing prevalence globally, alongside the epidemic of obesity. Unlike in adults, there are no data on children with uncontrolled hypertension and their future risk of hard cardiovascular and cerebrovascular outcomes. However, hypertension in childhood is linked to hypertensive-mediated organ damage (HMOD) which is often reversible if treated appropriately. Despite differing guidelines regarding the threshold for defining hypertension, there is consensus that early recognition and prompt management with lifestyle modification escalating to antihypertensive medication is required to ameliorate adverse outcomes. Unfortunately, many unknowns remain regarding pathophysiology and optimum treatment of childhood hypertension.

Lifestyle Interventions for Elevated Blood Pressure in Childhood-Approaches and Outcomes

PURPOSE OF REVIEW

The purpose of this review is to provide an overview of existing and emerging lifestyle treatments in the clinical management of primary elevated blood pressure and hypertension in pediatric patients. The authors hope to expand the knowledge base surrounding pediatric hypertension and update clinicians on best practices to improve outcomes.

RECENT FINDINGS

Elevated blood pressure is traditionally addressed with broad lifestyle recommendations such as limiting salt consumption and losing weight. This approach is not well adapted for pediatric patients. Novel and often underutilized approaches to the treatment of hypertension in pediatrics include psychological counseling for behavior modification, circadian nutrition, consistent use of interdisciplinary teams, manipulation of macronutrients, stress management, technology-infused interventions, and systemic changes to the food environment. Elevated blood pressure is a pervasive condition affecting cardiovascular disease and mortality risk. Increasingly, pediatric patients are presenting with elevated blood pressure with etiologies known to be affected by lifestyle behaviors. Weight management, dietary modifications, and daily physical activity are well-researched methods for improving individual blood pressure measurements. These strategies can sometimes be as effective as pharmacological interventions at lowering blood pressure. However, compliance with these individual recommendations is not consistent and has led to unsatisfactory results. There are emerging treatment trends that may provide non-traditional and more effective non-pharmacologic routes to blood pressure management in pediatric patients.

High blood pressure in children and adolescents: current perspectives and strategies to improve future kidney and cardiovascular health

Hypertension is one of the most common causes of preventable death worldwide. The prevalence of pediatric hypertension has increased significantly in recent decades. The cause of this is likely multifactorial, related to increasing childhood obesity, high dietary sodium intake, sedentary lifestyles, perinatal factors, familial aggregation, socioeconomic factors, and ethnic blood pressure (BP) differences. Pediatric hypertension represents a major public health threat. Uncontrolled pediatric hypertension is associated with subclinical cardiovascular disease and adult-onset hypertension. In children with chronic kidney disease (CKD), hypertension is also a strong risk factor for progression to kidney failure. Despite these risks, current rates of pediatric BP screening, hypertension detection, treatment, and control remain suboptimal. Contributing to these shortcomings are the challenges of accurately measuring pediatric BP, limited access to validated pediatric equipment and hypertension specialists, complex interpretation of pediatric BP measurements, problematic normative BP data, and conflicting society guidelines for pediatric hypertension. To date, limited pediatric hypertension research has been conducted to help address these challenges. However, there are several promising signs in the field of pediatric hypertension. There is greater attention being drawn on the cardiovascular risks of pediatric hypertension, more emphasis on the need for childhood BP screening and management, new public health initiatives being implemented, and increasing research interest and funding. This article summarizes what is currently known about pediatric hypertension, the existing knowledge-practice gaps, and ongoing research aimed at improving future kidney and cardiovascular health.